NCT05162846Completed
Michigan Genetic Hereditary Testing (MiGHT)
Methods for Increasing Genetic Testing Uptake in Michigan
Source: ClinicalTrials.gov · Last updated 18 Aug 2026
Brief summary (registry, in English)
The primary purpose of this study is to compare three interventions, two experimental and one standard of care (usual care), to see if the experimental interventions will increase the likelihood of a participant obtaining guideline-concordant genetic testing. Eligible participants will be randomized (assigned) to one of the following interventions: 1) Virtual genetics navigator, a mobile-optimized website, designed by the investigators, that delivers tailored messages and content; 2) two motivational interviewing (MI) telephone calls delivered by trained genetics health coaches; or 3) usual care.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 793 (actual)
- First submitted
- 8 Dec 2021
- Start date
- 21 Apr 2022
- Primary completion date
- 13 Jul 2025
- Lead sponsor
- University of Michigan Rogel Cancer Center
- NCT number
- NCT05162846
What you commit to
- Study type: Interventional
- Participants enrolled: 793
- From 21 Apr 2022 to the primary completion date, 13 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior clinical germline genetic testing for cancer or already have an upcoming appointment scheduled with a genetics provider
Who the study is looking for
- Able to speak and read English
- Access to the internet
- Completed the Family Health History Tool (FHHT)
- Meeting clinical criteria for genetic evaluation due to any of the below:
- Personal history of Breast cancer either:
- i. Diagnosed under 50
- ii. Personal or family history of triple negative breast cancer
- iii. Ashkenazi Jewish ancestry
- iv. Male proband
- v. 1st or 2nd degree relative with ovarian cancer, pancreatic cancer, breast cancer diagnosed under 50, or male breast cancer
- Personal history of prostate cancer either:
- i. Diagnosed under 50
- ii. Ashkenazi Jewish ancestry
- iii. 1st or 2nd degree relative with ovarian cancer, pancreatic cancer, breast cancer diagnosed under 50, or male breast cancer
- Personal history of any cancer or no personal history of cancer with either:
- i. PREMM score ≥ 2.5%
- ii. 1st degree relative with pancreatic, or male breast cancer
- iii. 1st or 2nd degree relative with ovarian cancer
- iv. 1st degree relative with any of these cancers diagnosed under 50: colon, endometrial, or breast
- v. Ashkenazi Jewish ancestry and 1st or 2nd degree relative with breast cancer
- Personal history of endometrial cancer diagnosed under 50
- Personal history of colorectal cancer diagnosed under 50
- Personal history of renal cancer diagnosed under 46
- Personal history of sarcoma diagnosed under 46 and a 1st or 2nd degree relative with sarcoma, breast cancer, or brain cancer diagnosed under 56
- Personal history of brain cancer diagnosed under 46 and a 1st or 2nd degree relative with sarcoma, breast cancer, or brain cancer diagnosed under 56
- Personal history of any two of the following cancers with at least one of them diagnosed under 46: breast, sarcoma, or brain
- Personal history of ovarian cancer
- Personal history of pancreatic cancer
- Personal history of adrenal cortical carcinoma
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Michigan Rogel Cancer Center Coordinator of this site? Confirm its status | Ann Arbor | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.